Streptomyces Fradiae Patents (Class 435/896)
-
Patent number: 6670505Abstract: A process for recovering a desired organic acid from a solution includes the steps of: providing an aqueous solution including at least one desired organic acid or its acid anion; adjusting the proton concentration in the aqueous solution to a desired level, with the desired proton concentration being selected, at least in part, by the amount of available protons needed to associate with the acid anions of the desired organic acid(s) to be recovered and/or acid anions that are weaker than the desired organic acids; and recovering at least a portion of the at least one desired organic acid from the aqueous phase. The desired proton concentration can be based on the amount of available protons being greater than, less than or substantially equal, to the amount of protons needed to associate with the anion of the desired organic acid(s) and acid anions that are weaker than the desired organic acid(s).Type: GrantFiled: March 7, 2000Date of Patent: December 30, 2003Assignee: Eastman Chemical CompanyInventors: Nick Allen Collins, Mark Robert Shelton, George William Tindall, Steven Thomas Perri, Ruairi Seosamh O'Meadhra, Chester Wayne Sink, Bhaskar Krishna Arumugam, John Clark Hubbs
-
Patent number: 5698420Abstract: Preparation of 4'-deoxy-O-mycaminosyltylonolide by feeding repromicin to a fermentation broth of a strain of the microorganism Streptomyces fradiae (ATCC 31733) under aerobic conditions in an aqueous nutrient medium containing inorganic salts and assimilable sources of carbon and nitrogen.Type: GrantFiled: November 26, 1996Date of Patent: December 16, 1997Assignee: Pfizer Inc.Inventor: Lapyuen H. Lam
-
Patent number: 5665586Abstract: According to the present invention, a novel protease derived from Streptomyces fradiae for cleaving the C-terminal of a glutamic acid residue in an amino acid sequence of a polypeptide and a production method for this protease from Streptomyces fradiae are provided, and the characteristics of this protease are made clear. Further, DNA sequences for encoding this protease and a prepropeptide are also made clear. The protease specific to glutamic acid can be used for a variety of purposes including analysis of a protein and cleavage of a peptide chain at a desired site in a fusion protein.Type: GrantFiled: November 18, 1994Date of Patent: September 9, 1997Assignee: Shionogi & Co., Ltd.Inventors: Etsuo Nakamura, Hiroshige Tsuzuki, Kengo Kitadokoro, Masaru Shin, Hiroshi Teraoka
-
Patent number: 5047240Abstract: Method for producing a proteolytic complex formed after cultivation of a strain of Streptomyces fradiae while maintaining the pH of the culture medium between 7 and 7.5, and extracting said complex by filtration in the presence of a clarifying agent and ultrafiltration on a specific membrane and finally atomization; the invention also relates to the new proteolytic complex thus obtained and its applications in zootechny due to its stimulating effect on the activity of the pancreas.Type: GrantFiled: April 18, 1988Date of Patent: September 10, 1991Inventor: Michel Hooreman
-
Patent number: 4994270Abstract: New peptide antibiotic A54145, individual A54145 components A, A.sub.1, B, B.sub.1, C, D, E and F and their pharmaceutically acceptable salts, are useful antibacterial agents which also improve growth performance in animals, especially poultry. Biologically pure cultures of the A54145-producing Streptomyces fradiae cultures NRRL 18158, NRRL 18159 and NRRL 18160 cultures and methods of making antibiotic A54145 using those cultures are also provided.Type: GrantFiled: April 11, 1988Date of Patent: February 19, 1991Assignee: Eli Lilly and CompanyInventors: LaVerne D. Boeck, David S. Fukuda, Jon S. Mynderse, Marvin M. Hoehn, Ralph E. Kastner, Harold R. Papiska
-
Patent number: 4977083Abstract: Improved processes for preparing A54145 components and cyclic peptide derivatives (A54145 compounds) comprising: (1) feeding alkanoic or alkenoic acids or alcohols, or esters or salts thereof, (2) feeding glucose at a rate from about 6-9 g/L/day, or (3) feeding enzymatic soy digest at a rate from about 2-4 g/L/day to an A54145-producing culture during its fermentation and recovering the A54145 compound, are provided.Type: GrantFiled: April 11, 1988Date of Patent: December 11, 1990Assignee: Eli Lilly and CompanyInventor: LaVerne D. Boeck
-
Patent number: 4939125Abstract: The O-acyl derivatives of urdamycin A exhibit an antibiotic or antitumoral activity.Type: GrantFiled: October 5, 1987Date of Patent: July 3, 1990Assignee: Hoechst AktiengesellschaftInventors: Axel Zeeck, Thomas Ciesiolka, Hans Zahner, Hannelore Drautz
-
Patent number: 4889809Abstract: The tlrC gene is a novel tylosin resistance-conferring gene isolated from Streptomyces fradiae and used to construct a number of cloning vectors for use in Streptomyces. One such cloning vector, plasmid pSKC10, can be obtained in S. fradiae JS87 under the accession number NRRL 18072. S. fradiae JS87 is the preferred host when the tlrC gene is used to select tylosin-resistant Streptomyces transformants.Type: GrantFiled: July 25, 1986Date of Patent: December 26, 1989Assignee: Eli Lilly and CompanyInventors: Virginia A. Birmingham, Karen L. Cox, Eugene T. Seno
-
Patent number: 4859655Abstract: A new substance, urdamycin G, has been found which, like its O-acyl derivatives, exhibits an antibiotic or antitumoral activity.Type: GrantFiled: August 26, 1987Date of Patent: August 22, 1989Assignee: Hoechst AktiengesellschaftInventors: Axel Zeeck, Thomas Ciesiolka, Jurgen Rohr, Hans Zahner, Hannelore Drautz
-
Patent number: 4843002Abstract: A novel method of selecting Streptomyces recombinant DNA-containing host cells and vectors useful in exemplifying the method are described. The vectors confer apramycin resistance to sensitive Streptomyces host cells and thus provide a convenient method of selecting Streptomyces transformants. The apramycin resistance-conferring gene used in the method is an acetyltransferase aac(3)IV gene and can be isolated from E. coli K12 BE1041/pKC309 (NRRL B-15827) on an .about.1.5 kb PstI-EcoRI restriction fragment.Type: GrantFiled: September 27, 1984Date of Patent: June 27, 1989Assignee: Eli Lilly and CompanyInventors: R. Nagaraja Rao, Richard K. Stanzak
-
Patent number: 4766066Abstract: The invention relates to a method and cloning vehicle for the expression of a functional polypeptide in Streptomyces. A recombinant DNA cloning vehicle was genetically engineered to bring the expression of the neomycin phosphotransferase gene under the control of the Escherichia coli bacteriophage .lambda.p.sub.L promoter.Type: GrantFiled: September 27, 1984Date of Patent: August 23, 1988Assignee: Eli Lilly and CompanyInventors: Stuart A. Kuhstoss, R. Nagaraja Rao
-
Patent number: 4753886Abstract: The present invention discloses selectable, recombinant DNA shuttle vectors for use in streptomycetes and E. coli. The shuttle vectors of the present invention are present at moderately high copy number. The invention further discloses transformants of the aforementioned vectors.Type: GrantFiled: August 10, 1984Date of Patent: June 28, 1988Assignee: Eli Lilly and CompanyInventors: Charles L. Hershberger, Jeffrey L. Larson
-
Patent number: 4745056Abstract: Cloning vectors are disclosed to obtain secretion of a desired protein from a host Streptomyces when a structural gene coding for the protein is inserted into the vector. The vector has: (1) regulatory DNA that includes a promoter sequence effective to start transcription in the host Streptomyces and DNA that encodes a ribosome-binding site; (2) a DNA sequence that codes for a signal sequence that occurs naturally in a Streptomyces strain or that derives from such a DNA sequence; and (3) at least one engineered restriction endonuclease recognition site positioned for the insertion of a structural gene, the DNA that encodes a signal sequence and attached structural gene being transcribed and translated together under the control of the regulatory DNA. Expression vectors are disclosed which include a structural gene coding for a desired protein so positioned. Streptomyces cells containing the vector and methods of using them to produce the desired protein are disclosed.Type: GrantFiled: October 23, 1984Date of Patent: May 17, 1988Assignee: Biotechnica International, Inc.Inventors: Sonia Guterman, Janice Pero, Phillips Robbins
-
Patent number: 4698307Abstract: The present invention disclosed novel recombinant DNA cloning vectors including pMND1000 and vectors derived therefrom for use in Streptomyces and related organisms. These novel cloning vectors contain genetic markers that provide antibiotic resistance or colorimetric selectivity to the host cells. The invention further comprises transformants of the aforementioned vectors.Type: GrantFiled: August 10, 1984Date of Patent: October 6, 1987Assignee: Eli Lilly and CompanyInventors: James A. Mabe, Walter M. Nakatsukasa
-
Patent number: 4683206Abstract: The present invention disclosed novel recombinant DNA cloning vectors for use in Streptomyces and related organisms. These novel cloning vectors contain genetic markers that provide antibiotic resistance or colorimetric selectivity to the host cells. The invention further comprises transformants of the aforementioned vectors.Type: GrantFiled: August 10, 1984Date of Patent: July 28, 1987Assignee: Eli Lilly and CompanyInventors: James A. Mabe, Walter M. Nakatsukasa
-
Patent number: 4468462Abstract: The present invention discloses selectable recombinant DNA cloning vectors for use in Streptomyces.Type: GrantFiled: December 22, 1982Date of Patent: August 28, 1984Assignee: Eli Lilly and CompanyInventors: Nancy E. Malin, Jeffrey T. Fayerman, Michael D. Jones, James A. Mabe, Walter M. Nakatsukasa
-
Patent number: 4460691Abstract: A novel plasmid cloning vector, designated pUC13, can be used, advantageously, in recombinant DNA work. This plasmid has been identified as a prophage. The procedures used to recognize this prophage can be used to recognize other prophages in Streptomyces.Type: GrantFiled: August 10, 1981Date of Patent: July 17, 1984Assignee: The Upjohn CompanyInventor: Shiau-Ta Chung
-
Patent number: 4440857Abstract: A new microorganism, Streptomyces fradiae NRRL 12201, which produces mycarosyltylactone (5-O-mycarosyl-20-dihydro-20,23-dideoxytylonolide) and a process for preparing tylactone (20-dihydro-20,23-dideoxytylonolide) and mycarosyltylactone by submerged aerobic fermentation of this microorganism, or a mycarosyltylactone-producing mutant or recombinant thereof, are provided.Type: GrantFiled: March 18, 1982Date of Patent: April 3, 1984Assignee: Eli Lilly and CompanyInventors: Eugene T. Seno, Richard H. Baltz
-
Patent number: 4438197Abstract: The antibacterial compound DC-38-V is produced by culturing a microorganism belonging to the genus Streptomyces.Type: GrantFiled: April 16, 1982Date of Patent: March 20, 1984Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Fusao Tomita, Yuzuru Matsuda, Kunikatsu Shirahata, Keiichi Takahashi, Hirofumi Nakano, Tomoyasu Sato, Shuji Okubo, Nobuo Nakamura
-
Patent number: 4423148Abstract: 20-Dihydro-20-deoxy-23-de(mycinosyloxy)tylosin (20-deoxo-DMOT), specified 2'-acyl ester derivatives, and their acid addition salts are useful intermediates and antibacterial agents. Methods of preparing 20-deoxo-DMOT and 5-O-mycaminosyltylactone by fermentation of Streptomyces fradiae ATCC 31733 are included.Type: GrantFiled: July 2, 1982Date of Patent: December 27, 1983Assignee: Eli Lilly and CompanyInventor: Gene M. Wild
-
Patent number: 4419447Abstract: 23-Demycinosyltylosin (DMT) which has the formula: ##STR1## 20-dihydro-DMT, specified acyl ester derivatives, and their acid addition salts are useful antibacterial agents. Improved methods of making 5-O-mycaminosyltylonolide (OMT) and 20-dihydro-OMT by mild acid hydrolysis of DMT and 20-dihydro-DMT, respectively, are included.Type: GrantFiled: May 6, 1981Date of Patent: December 6, 1983Assignee: Eli Lilly and CompanyInventors: Richard H. Baltz, Gene M. Wild, Eugene T. Seno
-
Patent number: 4400465Abstract: A process for preparing a B30-threonine-insulin which comprising reacting a des-B30-insulin with an excess amount of threonine derivative in the presence of an enzyme specifically acting on the basic-amino-acid carbonyl in peptide bondings.Type: GrantFiled: December 31, 1981Date of Patent: August 23, 1983Assignee: Shionogi & Co., Ltd.Inventors: Kazuyuki Morihara, Tatsushi Oka, Hiroshige Tsuzuki
-
Patent number: 4385116Abstract: 2'"-O-demethylmacrocin (DOMM) which has the formula: ##STR1## 20-dihydro-DOMM, 2'"-O-demethyllactenocin (DOML), 20-dihydro-DOML, specified acyl ester derivatives, and their acid addition salts are useful antibacterial agents.Type: GrantFiled: July 15, 1980Date of Patent: May 24, 1983Assignee: Eli Lilly and CompanyInventors: Richard H. Baltz, Gene M. Wild, Eugene T. Seno
-
Patent number: 4376823Abstract: A method of increasing the yield of a desired product, such as an antibiotic, by an organism which normally must first become inducibly resistant to that product before it can produce the product in maximum yields comprises producing constitutively resistant cells of the organism by supplementing a culture of the organism with an agent in which only cells able to specifically modify the 23S ribosomal RNA constitutively, rather than inducibly, survive thereby producing an organism in which the resistance to the product is expressed without the need for activation by the induction process; followed by purification and utilization of that organism for increased product production.Type: GrantFiled: June 18, 1981Date of Patent: March 15, 1983Assignee: Wisconsin Alumni Research FoundationInventor: Bernard Weisblum
-
Patent number: 4366247Abstract: A process for preparing tylactone (20-dihydro-20,23-dideoxytylonolide), which has the formula: ##STR1## by submerged aerobic fermentation of Streptomyces fradiae NRRL 12188 or a tylactone-producing mutant or recombinant thereof is provided.Type: GrantFiled: July 2, 1980Date of Patent: December 28, 1982Assignee: Eli Lilly and CompanyInventors: Richard H. Baltz, Eugene T. Seno
-
Patent number: 4334019Abstract: 23-De(mycinosyloxy)tylosin (DMOT) which has the formula: ##STR1## 20-dihydro-DMOT, specified acyl ester derivatives, and the acid addition salts thereof are useful antibacterial agents. New methods of making 23-deoxy-5-O-mycaminosyltylonolide (DOMT) and 20-dihydro-DOMT by mild acid hydrolysis of DMOT and 20-dihydro-DMOT, respectively, are included.Type: GrantFiled: May 8, 1981Date of Patent: June 8, 1982Assignee: Eli Lilly and CompanyInventors: Richard H. Baltz, Gene M. Wild, Eugene T. Seno
-
Patent number: 4320196Abstract: A process for preparing a B30-threonine-insulin which comprising reacting a des-B30-insulin with an excess amount of threonine derivative in the presence of an enzyme specifically acting on the basic-amino-acid carbonyl in peptide bondings.Type: GrantFiled: April 9, 1980Date of Patent: March 16, 1982Assignee: Shionogi & Co., Ltd.Inventors: Kazuyuki Morihara, Tatsushi Oka, Hiroshige Tsuzuki
-
Patent number: 4304856Abstract: 20-Dihydro-20-deoxy-23-demycinosyltylosin (DH-DO-DMT), 20-dihydro-20-deoxy-5-O-mycaminosyltylonolide (DH-DO-OMT), specified acyl ester derivatives, and their acid addition salts are useful intermediates and antibacterial agents. Methods of preparing DH-DO-DMT and DH-DO-OMT by fermentation of Streptomyces fradiae and the microorganism S. fradiae ATCC 31733 are included.Type: GrantFiled: November 10, 1980Date of Patent: December 8, 1981Assignee: Eli Lilly and CompanyInventors: Richard H. Baltz, Herbert A. Kirst, Gene M. Wild, Eugene T. Seno
-
Patent number: 4212941Abstract: 9-(2-O-Acyl-.beta.-D-arabinofuranosyl)adenine compounds and their production by enzymatic removal of the 3-O-acyl and 5-O-acyl groups of a 9-(2,3-di-O-acyl-.beta.-D-arabinofuranosyl)adenine compound or a 9-(2,3,5-tri-O-acyl-.beta.-D-arabinofuranosyl)adenine compound. The monoester compounds are useful as antiviral agents. The compounds are water-soluble and lipophilic, thereby being adaptable to a wide variety of pharmaceutical formulations.Type: GrantFiled: May 23, 1977Date of Patent: July 15, 1980Assignee: Warner-Lambert CompanyInventor: David C. Baker
-
Patent number: 4170643Abstract: Novel aminoglycoside-aminocyclitol derivatives corresponding to the general formula: ##STR1## wherein R.sub.1 and R.sub.2, which are different, represent hydrogen or CH.sub.2 NH.sub.2 and R is selected from the group consisting of: ##STR2## wherein R.sub.3 represents NH.sub.2 or OH and R.sub.4 represents ##STR3## wherein R.sub.5 represents hydrogen or methyl and the pharmaceutically acceptable acid addition salts thereof.They are useful as antibiotics.Type: GrantFiled: April 13, 1977Date of Patent: October 9, 1979Assignee: LabazInventors: Stephan Gero, Daniel Mercier, Alain Olesker, Andre Cier